Navigation Links
Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
Date:7/15/2008

LAIYANG, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received approval from the Chinese State Food and Drug Administration ("SFDA") to start producing and distributing Radix Isatidis Dispersible Tablets.

Radix Isatidis is an herbal-based traditional Chinese medicine used to cure viral influenza. Radix Isatidis is very popular in China because people there believe it has fewer side affects than western medicines. Most Radix Isatidis products are in powder form, which has to be dissolved in hot water. Genesis will be the only company in China to manufacture Radix Isatidis in dispersible tablet form. Radix Isatidis Dispersible Tablets will be more convenient to take, easier to absorb and are more stable than Radix Isatidis products in powder form.

Radix Isatidis Dispersible Tablets will be sold over the counter in pharmacies, a rapidly growing distribution channel for drugs in China. The Company will start distributing Radix Isatidis Dispersible Tablets within three months, and will make this medicine widely available to customers throughout China.

Annual sales of Radix Isatidis in China are estimated to be over US$1.43 billion. The Company estimates that its sales of Radix Isatidis Dispersible Tablets in fiscal year 2009 ending June 30, 2009 will be approximately US$4.2 million and an estimated US$10 million in fiscal year 2010.

Genesis has all of manufacturing equipment needed to produce Radix Isatidis Dispersible Tablets, and has concluded its marketing research and planning for this new product. The Company estimates that its first year working capital and marketing expenses will be approximately US$1.0 million.

"We are pleased to receive approval from the SFDA to produce and distribute Radix Isatidis Dispersible Tablets," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We will distribute this new drug through our existing nationwide marketing and distribution network, and believe it will quickly become popular among a wide range of customers, from young to old people."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO

Tel: +1-954-727-8436

Email: genesispharm@gmail.com

Web: http://www.genesis-china.net

CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web: http://www.ccgelite.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurogenesis in the adult brain: The association with stress and depression
2. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
3. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
4. What roles does TSP-1 play in liver fibrogenesis?
5. Genesis Pharmaceuticals Donates Medicine to China Sichuan Earthquake Relief
6. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
7. Cardiogenesis Reports First Quarter 2008 Results
8. Effect of mutant p53 stability on tumorigenesis and drug design
9. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
10. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
11. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: